Get started
MiMedx Group, IncMiMedx Group, IncMiMedx Group, Inc

MiMedx Group, Inc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MDXG chart


Full chart

MDXG upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.33 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
15.79
Basic EPS (TTM)
0.67 USD
Net income (FY)
‪58.23 M‬ USD
Revenue (FY)
‪321.48 M‬ USD
Shares float
‪114.62 M‬
Beta (1Y)
0.96

Employees


Employees (FY)
895
Change (1Y)
+28 +3.23%
Revenue / Employee (1Y)
‪359.19 K‬ USD
Net income / Employee (1Y)
‪75.35 K‬ USD

About MiMedx Group, Inc


Sector
Health Technology
Industry
Medical Specialties
CEO
Joseph H. Capper
Website
mimedx.com
Headquarters
Marietta
Founded
1985
FIGI
BBG000RJ6FL5
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

MDXG news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MDXG is 9.33 USD — it has decreased by −1.95% in the past 24 hours. Watch MiMedx Group, Inc stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MiMedx Group, Inc stocks are traded under the ticker MDXG.
MDXG stock has risen by 20.80% compared to the previous week, the month change is a 56.75% rise, over the last year MiMedx Group, Inc has showed a 27.98% increase.
We've gathered analysts' opinions on MiMedx Group, Inc future price: according to them, MDXG price has a max estimate of 16.00 USD and a min estimate of 11.00 USD. Watch MDXG chart and read a more detailed MiMedx Group, Inc stock forecast: see what analysts think of MiMedx Group, Inc and suggest that you do with its stocks.
MDXG reached its all-time high on Jan 29, 2018 with the price of 18.25 USD, and its all-time low was 0.31 USD and was reached on Aug 22, 2007. View more price dynamics on MDXG chart.
See other stocks reaching their highest and lowest prices.
MDXG stock is 3.08% volatile and has beta coefficient of 0.96. Track MiMedx Group, Inc stock price on the chart and check out the list of the most volatile stocks — is MiMedx Group, Inc there?
Today MiMedx Group, Inc has the market capitalization of ‪1.33 B‬, it has decreased by −1.84% over the last week.
Yes, you can track MiMedx Group, Inc financials in yearly and quarterly reports right on TradingView.
MiMedx Group, Inc is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
MDXG earnings for the last quarter are 0.05 USD per share, whereas the estimation was 0.04 USD resulting in a 13.64% surprise. The estimated earnings for the next quarter are 0.07 USD per share. See more details about MiMedx Group, Inc earnings.
MiMedx Group, Inc revenue for the last quarter amounts to ‪84.06 M‬ USD, despite the estimated figure of ‪82.64 M‬ USD. In the next quarter, revenue is expected to reach ‪89.40 M‬ USD.
MDXG net income for the last quarter is ‪8.10 M‬ USD, while the quarter before that showed ‪17.63 M‬ USD of net income which accounts for −54.07% change. Track more MiMedx Group, Inc financial stats to get the full picture.
No, MDXG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 895.00 employees. See our rating of the largest employees — is MiMedx Group, Inc on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MiMedx Group, Inc EBITDA is ‪66.74 M‬ USD, and current EBITDA margin is 12.61%. See more stats in MiMedx Group, Inc financial statements.
Like other stocks, MDXG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MiMedx Group, Inc stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MiMedx Group, Inc technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MiMedx Group, Inc stock shows the strong buy signal. See more of MiMedx Group, Inc technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.